Celis E - Search Results

1

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.

Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E. Markovic SN, et al. Among authors: celis e. Am J Clin Oncol. 2006 Aug;29(4):352-60. doi: 10.1097/01.coc.0000217877.78473.a4. Am J Clin Oncol. 2006. PMID: 16891861 Clinical Trial.

2

A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood.

Markovic SN, Nevala WK, Uhl CB, Celis E, McKean DJ. Markovic SN, et al. Among authors: celis e. Clin Exp Immunol. 2006 Sep;145(3):438-47. doi: 10.1111/j.1365-2249.2006.03157.x. Clin Exp Immunol. 2006. PMID: 16907911 Free PMC article.

3

Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model.

Kalaaji AN, Lu J, Markovic SN, Celis E, Pittelkow MR. Kalaaji AN, et al. Among authors: celis e. Cytokine. 2010 Mar;49(3):287-93. doi: 10.1016/j.cyto.2009.11.016. Epub 2010 Jan 8. Cytokine. 2010. PMID: 20060741

4

Challenges in the development of effective peptide vaccines for cancer.

Buteau C, Markovic SN, Celis E. Buteau C, et al. Among authors: celis e. Mayo Clin Proc. 2002 Apr;77(4):339-49. doi: 10.4065/77.4.339. Mayo Clin Proc. 2002. PMID: 11936929 Review.

5

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.

Melanoma Study Group of the Mayo Clinic Cancer Center; Celis E. Melanoma Study Group of the Mayo Clinic Cancer Center, et al. Among authors: celis e. Cancer. 2007 Jul 1;110(1):203-14. doi: 10.1002/cncr.22744. Cancer. 2007. PMID: 17541944 Free article. Clinical Trial.

6

T-cell epitope peptide vaccines.

Elsawa SF, Rodeberg DA, Celis E. Elsawa SF, et al. Among authors: celis e. Expert Rev Vaccines. 2004 Oct;3(5):563-75. doi: 10.1586/14760584.3.5.563. Expert Rev Vaccines. 2004. PMID: 15485336 Free article. Review.

7

Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Rodeberg DA, et al. Among authors: celis e. Clin Cancer Res. 2005 Jun 15;11(12):4545-52. doi: 10.1158/1078-0432.CCR-04-2235. Clin Cancer Res. 2005. PMID: 15958640 Free PMC article.

8

Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.

Davila E, Kennedy R, Celis E. Davila E, et al. Among authors: celis e. Cancer Res. 2003 Jun 15;63(12):3281-8. Cancer Res. 2003. PMID: 12810660

9

Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function.

Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R, Celis E. Giuntoli RL 2nd, et al. Among authors: celis e. Clin Cancer Res. 2002 Mar;8(3):922-31. Clin Cancer Res. 2002. PMID: 11895927

10

Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.

Kobayashi H, Lu J, Celis E. Kobayashi H, et al. Among authors: celis e. Cancer Res. 2001 Oct 15;61(20):7577-84. Cancer Res. 2001. PMID: 11606397

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters